LEADER 04095nam  22005895  450 
001 9910300273203321
005 20251116195431.0
010   $a9783319724164
010   $a3319724169
024 7 $a10.1007/978-3-319-72416-4
035   $a(CKB)4100000002892189
035   $a(MiAaPQ)EBC5372082
035   $a(DE-He213)978-3-319-72416-4
035   $a(PPN)225547562
035   $a(EXLCZ)994100000002892189
100   $a20180319d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug Interactions in Infectious Diseases: Antimicrobial Drug Interactions /$fedited by Manjunath P. Pai, Jennifer J. Kiser, Paul O. Gubbins, Keith A. Rodvold
205   $a4th ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Humana,$d2018.
215   $a1 online resource (576 pages)
225 1 $aInfectious Disease
311 08$a9783319724157 
311 08$a3319724150 
327   $aBeta-Lactam Antibiotics -- Macrolides, Azalides, and Ketolides -- Quinolones -- Glycopeptides, Lipopeptides, and Lipoglycopeptides -- Miscellaneous Antibiotics -- Drugs for Tuberculosis -- Drug Interactions in HIV: Protease and Integrase Inhibitors -- Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors -- Hepatitis B and Hepatitis C Antiviral Agents -- Drug Interactions of Non-HIV Antiviral Agents -- Antifungal Agents -- Antimalarial Agents -- Antiprotozoal and Anthelminthic Agents.
330   $aThe 4th edition of Drug Interactions in Infectious Diseases is being split into two separate volumes ? ?Mechanisms and Models of Drug Interactions? and ?Antimicrobial Drug Interactions?. This volume, ?Antimicrobial Drug Interactions,? delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
410  0$aInfectious Disease
606   $aPharmaceutical technology
606   $aInfectious diseases
606   $aPharmacy
606   $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010
606   $aInfectious Diseases$3https://scigraph.springernature.com/ontologies/product-market-codes/H33096
606   $aPharmacy$3https://scigraph.springernature.com/ontologies/product-market-codes/F00008
615  0$aPharmaceutical technology.
615  0$aInfectious diseases.
615  0$aPharmacy.
615 14$aPharmaceutical Sciences/Technology.
615 24$aInfectious Diseases.
615 24$aPharmacy.
676   $a615.7045
702   $aPai$b Manjunath P.$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aKiser$b Jennifer J$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aGubbins$b Paul O$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aRodvold$b Keith$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300273203321
996   $aDrug Interactions in Infectious Diseases$91745060
997   $aUNINA